New approaches to stratify multiple myeloma patients based on prognosis and therapeutic
decision-making, or prediction, are needed since patients are currently managed in a similar …

Proteasome inhibitors are one of the most important classes of agents to have emerged for
the treatment of multiple myeloma in the past two decades, and now form one of the …

Multiple myeloma (MM, plasma cell myeloma) is a malignant hematologic disease
characterized by the clonal proliferation of malignant plasma cells. The treatment of MM has …

Implant-associated infection is a major threat affecting the success of orthopedic surgeries.
Although various materials scavenge bacteria by generating reactive oxygen species (ROS) …

To date, the choice of therapy for an individual multiple myeloma patient has been based on
clinical factors such as age and comorbidities. The widespread evolution, validation, and …

Some genetic abnormalities of multiple myeloma (MM) detected more than two decades ago
remain major prognostic factors. In recent years, the introduction of cutting-edge genomic …

The Hi-C method is widely used to study the functional roles of the three-dimensional (3D)
architecture of genomes. Here, we integrate Hi-C, whole-genome sequencing (WGS) and …

Patients with multiple myeloma (MM) have experienced a markedly improved survival over
the past 25 years, thanks in part to the availability of new drugs [1]. However, a subgroup of …

Beyond its well-admitted role in development and organogenesis, it is now clear that the
transcription factor c-Maf has owned its place in the realm of immune-related transcription …

Simple Summary As convergence points of signaling cascades, transcription factors (TFs)
play a crucial role in cell physiology, including B cell differentiation, and are deregulated in …